April 18, 2017 / 5:47 AM / 3 months ago

BRIEF-Geneuro initiates Phase 2a study with GNbAC1 in type 1 diabetes in Australia

1 Min Read

April 18 (Reuters) - Geneuro SA:

* Geneuro initiates Phase 2a study with GNbAC1 in type 1 diabetes in Australia

* Type 1 diabetes is second GNbAC1's indication after multiple sclerosis

* Placebo controlled randomized phase 2a study evaluates drug candidate targeting potential causal factor in 60 recently diagnosed adults

* Results expected by Q3 2018

* Placebo-Controlled, randomized phase 2a study will evaluate GNbAC1 in 60 recently diagnosed adults at over 10 centers in Australia

* Primary endpoint will be safety in this new patient population Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below